◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

药石科技

药石科技
Loading...
Key Metrics
Market Cap
8.3B ($1.2B)
P/E Ratio
N/A
P/B Ratio
N/A
Revenue
1.7B
Net Income
220.0M
Gross Margin
N/A
Op. Margin
14.9%
Net Margin
13.0%
ROE
7.4%
ROA
4.5%
D/E
0.65
Dividend Yield
N/A
EPS
1.10
Current Ratio
3.63
Price History
Company Info
IndustryM73研究和试验发展
Market SegmentChiNext
CurrencyCNY
Fiscal Year2024
Business Overview

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including ...

Peers
工商银行
601398
2.7T
P/E: 7.6
建设银行
601939
2.5T
P/E: 7.2
农业银行
601288
2.4T
P/E: 8.7
中国海油
600938
2.0T
P/E: 16.2
宁德时代
300750
1.9T
P/E: 25.6
贵州茅台
600519
1.8T
P/E: 20.1
中国银行
601988
1.8T
P/E: 7.3
中国人寿
601628
1.2T
P/E: 6.9
Financial Statements
Loading financials...
Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 药石科技

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, full development, registration, and post-approval; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. PharmaBlock Sciences (Nanjing), Inc. was founded in 2006 and is based in Nanjing, the People's Republic of China.


Ticker300725
ExchangeSZSE
Sector证监会行业分类
IndustryM73研究和试验发展
NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...